Phase 1 study to evaluate the safety and efficacy of jyuzentaihoto in infantile anal fistula

Phase 1 study to evaluate the safety and efficacy of jyuzentaihoto in infantile anal fistula - Safety and efficacy of jyuzentaihoto in infantile anal fistula

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021336

Enrollment

Registered

2016-03-04

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infantile anal fistula

Interventions

jyuzenntaihoto observe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: With anal fistula, no subjective symptoms,

Exclusion criteria

Exclusion criteria: Any of the following: currently receiving a drug therapy, currently having chronic diseases such as heart, lung, kidney, gastrointestinal, and inflammatory diseases, suffering from invasive cancer within five years, suffering from non-invasive cancer within a year, and having taken Kampo medicine within 2 weeks.

Design outcomes

Primary

Measure	Time frame
rate of cure after two and four weeks	—

Secondary

Measure	Time frame
The influence on gut flora and the safety after the administration of jyuzentaihoto	—

Countries

Japan

Contacts

Public ContactKeiko Ogawa

KKanazawa University Department of Kampo Medicine

okeiko@med.kanazawa-u.ac.jp076-265-2918

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026